Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Boston, Massachusetts, USA.
J Clin Invest. 2011 Apr;121(4):1549-60. doi: 10.1172/JCI44539. Epub 2011 Mar 14.
Elite controllers represent a unique group of HIV-1-infected persons with undetectable HIV-1 replication in the absence of antiretroviral therapy. However, the mechanisms contributing to effective viral immune defense in these patients remain unclear. Here, we show that compared with HIV-1 progressors and HIV-1-negative persons, CD4+ T cells from elite controllers are less susceptible to HIV-1 infection. This partial resistance to HIV-1 infection involved less effective reverse transcription and mRNA transcription from proviral DNA and was associated with strong and selective upregulation of the cyclin-dependent kinase inhibitor p21 (also known as cip-1 and waf-1). Experimental blockade of p21 in CD4+ T cells from elite controllers resulted in a marked increase of viral reverse transcripts and mRNA production and led to higher enzymatic activities of cyclin-dependent kinase 9 (CDK9), which serves as a transcriptional coactivator of HIV-1 gene expression. This suggests that p21 acts as a barrier against HIV-1 infection in CD4+ T cells from elite controllers by inhibiting a cyclin-dependent kinase required for effective HIV-1 replication. These data demonstrate a mechanism of host resistance to HIV-1 in elite controllers and may open novel perspectives for clinical strategies to prevent or treat HIV-1 infection.
精英控制者是一组独特的 HIV-1 感染者群体,他们在没有抗逆转录病毒治疗的情况下 HIV-1 复制无法被检测到。然而,这些患者中有效病毒免疫防御的机制仍不清楚。在这里,我们发现与 HIV-1 进展者和 HIV-1 阴性个体相比,精英控制者的 CD4+T 细胞对 HIV-1 感染的敏感性较低。这种对 HIV-1 感染的部分抵抗涉及到从前病毒 DNA 进行更有效的逆转录和 mRNA 转录,并且与 cyclin-dependent kinase inhibitor p21(也称为 cip-1 和 waf-1)的强烈和选择性上调有关。在精英控制者的 CD4+T 细胞中实验性阻断 p21,导致病毒逆转录和 mRNA 产生的显著增加,并导致作为 HIV-1 基因表达转录共激活因子的 cyclin-dependent kinase 9(CDK9)的酶活性升高。这表明 p21 通过抑制 HIV-1 复制所需的 cyclin-dependent kinase,在精英控制者的 CD4+T 细胞中充当 HIV-1 感染的屏障。这些数据表明了精英控制者中宿主对 HIV-1 的抵抗机制,并可能为预防或治疗 HIV-1 感染的临床策略开辟新的前景。